Victoria Link Limited

Industrial Research Limited

Agresearch Limited

University of Otago

The Malaghan Institute of Medical Research

Callaghan Innovation Research Limited

Regan James Anderson

Ian Francis Hermans

David Samuel Larsen

Benjamin Jason Compton

Colin Malcolm Hayman

Gavin Frank Painter

Franca Ronchese

Karen Anne Johnston

Gary Brian Evans

Keith Clinch

Ashley Jarvis

Jacquie Lucille Harper

Anthony Mitchell

John Adrian Dickison

Paul Andrew Benjes

Wayne Bruce Severn

Jeremy David Jones

Gurmit Singh-Gill

The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.

Amino sphingoglycolipid analogues

The invention relates to sphingoglycolipid analogs and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

Conjugate compounds

The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

Sphingoglycolipid analogues

This invention relates to sphingoglycolipid analogs, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.

Organic compounds as proantigens for natural killer T cells

The present invention is directed to synthetic molecules having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosaccharide) activity, for use in the treatment and prevention of inflammatory or immune cell mediated diseases or disorders.

Synthetic molecules having immune activity

A novel method for the preparation of a compound of formula (I) from an N&#x2014;protected-D-mannosamine. A compound of formula (I) is a useful intermediate for the preparation of kiftnensine, a potent and selective mannosidase inhibitor. The method includes protecting the hydroxyl group at the C-6 position of an N&#x2014;protected-D-mannosamine, to give a 6&#x2014;O&#x2014;protected&#x2014;N&#x2014;protected-D-mannosamine; reducing the C-1 anomeric carbon atom of the 6&#x2014;O&#x2014;protected&#x2014;N&#x2014;protected-D-mannosamine to give a 6&#x2014;O&#x2014;protected&#x2014;N&#x2014;protected-D-mannitol; protecting the four hydroxyl groups of the 6&#x2014;O&#x2014;protected&#x2014;N&#x2014;protected-D-mannitol; and removing the nitrogen atom protecting group and optionally removing the C-6 oxygen atom protecting group to give the compound of formula (I): where Rand Rare each independently protecting groups which, together with the oxygen atoms to which they are attached, form a 5-, 6-, 7- or 8-membered ring; and Ris hydrogen or a protecting group.

Process for preparing kifunensine intermediate and kifunensine therefrom

Growing community of inventors

Lower Hutt, New Zealand

Gavin Frank Painter